LOS ANGELES–(BUSINESS WIRE)–Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: To our valued Kairos Pharma Shareholders, As…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
